Cardiopulmonary exercise testing on adaptive equipment in children and adults with Friedreich ataxia
Nicolette A. Cilenti,Jaclyn G. Tamaroff,Christopher J. Capiola,Walter Faig,Michael G. McBride,Stephen M. Paridon,Shannon O'Malley,Jonathan B. Edelson,David R. Lynch,Shana E. McCormack,Kimberly Y. Lin
DOI: https://doi.org/10.1002/mus.28085
2024-03-23
Muscle & Nerve
Abstract:In this pilot study utilizing adaptive equipment for cardiopulmonary exercise testing (CPET), we found that CPET is feasible in most individuals with Friedreich ataxia. We also identified which parameters are most reliably measured and found no significant change in CPET performance in those who completed repeat testing 1 year later. Introduction/Aims Traditional exercise is often difficult for individuals with Friedreich ataxia (FRDA), and evidence is limited regarding how to measure exercise performance in this population. We evaluated the feasibility, reliability, and natural history of adaptive cardiopulmonary exercise test (CPET) performance in children and adults with FRDA. Methods Participants underwent CPET on either an arm cycle ergometer (ACE) or recumbent leg cycle ergometer (RLCE) at up to four visits (baseline, 2 weeks, 4 weeks, and 1 year). Maximum work, oxygen consumption (peak VO2), oxygen (O2) pulse, and anaerobic threshold (AT) were measured in those who reached maximal volition. Test–retest reliability was assessed with intraclass coefficients, and longitudinal change was assessed using regression analysis. Results In our cohort (N = 23), median age was 18 years (interquartile range [IQR], 14–23), median age of FRDA onset was 8 years (IQR 6–13), median Friedreich Ataxia Rating Scale score was 58 (IQR 54–62), and GAA repeat length on the shorter FXN allele (GAA1) was 766 (IQR, 650–900). Twenty‐one (91%) completed a maximal CPET (n = 8, ACE and n = 13, RLCE). Age, sex, and GAA1 repeat length were each associated with peak VO2. Preliminary estimates demonstrated reasonable agreement between visits 2 and 3 for peak work by both ACE and RLCE, and for peak VO2, O2 pulse, and AT by RLCE. We did not detect significant performance changes over 1 year. Discussion Adaptive CPET is feasible in FRDA, a relevant clinical trial outcome for interventions that impact exercise performance and will increase access to participation as well as generalizability of findings.
neurosciences,clinical neurology